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The aim of this study was to investigate the antidiabetic effects of a Tibetan medicine, Tang-Kang-Fu-San (TKFS), on experimental
type 2 diabetes mellitus (T2DM) rats and to explore its underlying mechanisms. Firstly two major chemical compositions of TKFS,
gallic acid and curcumin, were characterized by HPLC fingerprint analysis. Next T2DM in rats was induced by high-fat diet and
a low-dose streptozotocin (STZ 35mg/kg). Then oral gavage administration of three different doses of TKFS (0.3 g/kg, 0.6 g/kg,
and 1.2 g/kg) was given to T2DM rats. Experimental results showed that TKFS dramatically reduced the levels of fasting blood
glucose, fasting blood insulin, triglyceride, total cholesterol, LDL cholesterol, and HDL cholesterol, even though it did not alter the
animal body weight.The downregulation of phosphorylation-AKT (p-AKT) and glucose transporter-4 (GLUT4) in skeletal muscle
of T2DM rats was restored and abnormal pathological changes in pancreas tissues were also improved. Our work showed that
TKFS could alleviate diabetic syndromes, maintain the glucose homeostasis, and protect against insulin resistance in T2DM rats,
and the improvement of AKT phosphorylation and GLUT4 translocation in skeletal muscle would be one of its possible underlying
mechanisms.
1. Introduction
Type 2 diabetes mellitus (T2DM) is a heterogeneous group
of metabolic disorders including deranged fat, protein, and
carbohydrate metabolism and featured by hyperglycemia
resulting from insulin resistance and inadequate insulin
secretion [1]. According to the cartographic picture of dia-
betes provided by the International Diabetes Federation,
T2DM has been a public health problem threatening both
developed and developing countries and carried over into our
next generations [1, 2]. Thus effective prevention and treat-
ment of T2DM will tremendously reduce the medical costs
and benefit the public health [1–3]. To date there are several
classes of oral antidiabetic medications including biguanides,
sulfonylureas,meglitinide, thiazolidinedione, dipeptidyl pep-
tidase 4 inhibitors, sodium-glucose cotransporter inhibitors,
and 𝛼-glucosidase inhibitors [4, 5]. However, due to their
existing adverse side effects and increasing costs [4], it is
still attracting the global research to seek novel therapies for
T2DM.
Experimental animal models provide us with great
opportunities to gain information about howdifferent genetic
and environmental factors are influencing T2DM and to
develop new approaches treating the disease. In the last
decades a number of animal models had been developed
via different chemical, surgical, or genetic ways to duplicate
the clinical features or complications of T2DM with varying
degrees of insulin resistance and 𝛽-cell failure [6]. In fact, due
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to the complexity of T2DM it is known that none of these
animal models can fully represent all diverse syndromes seen
in patients [6]. In recent years a nongenetic rat model, 𝛽-cell-
toxicity of streptozotocin (STZ) resulting in 𝛽-cell necrosis,
has been often used to combine with high-fat diet resulting in
𝛽-cell failure and insulin resistance [6, 7]; therefore, we also
chose this model to study the mechanisms and treatments of
T2DM.
Traditional Chinese Medicine (TCM) has long been
the foundation in the treatment and prevention of many
diseases and approximately 800 plants have been identified
in the treatment or prevention of T2DM [8]. Because of
their reputation for safety, efficacy, and low cost, there is
growing interest in research and pharmaceutical industry
to study TCM herbs as candidates for the prevention and
treatment of T2DM [8, 9]. Tang-Kang-Fu-San (TKFS), a
traditional Tibetanmedicine and a herbal formula developed
under a careful study of “rGyud-bzhi” (a principal textbook
of Tibetan medicine), has been used to treat T2DM for
many years in China, especially in the Qinghai-Tibet Plateau.
However, scientific evidence related to its antidiabetic efficacy
and exact mechanisms was still absent. Therefore, to better
cope with those challenges we chose combination of high-fat
diet and a low-dose STZ-induced T2DM rats as our animal
model and studied the antidiabetic effects and the possible
intracellular mechanisms of TKFS for treating the T2DM.
2. Materials and Methods
2.1. HPLC Method for Quantitative Analysis of Gallic Acid
and Curcumin. The herbal formula of TKFS was provided
by Tibet Autonomous Region Institute of Traditional Tibetan
Hospital. High performance liquid chromatography (HPLC)
analysis was used to analyze active constituents of gallic acid
and curcumin in TKFS. 0.5 g of TKFS powder was extracted
with 50mL of 50% methanol in an ultrasonic water bath
(50 : 50, v/v of methanol/water) for 20min. Gallic acid and
curcumin were purchased from Chengdu Must Biological
Technology Co., Ltd. (Chengdu, China). Their purities were
more than 98% and stock solutions were prepared by dissolv-
ing in methanol.
TheHPLCfingerprint study aswell as the quantitative and
qualitative analysis had been performed similarly to previous
studies [10, 11]. Shortly, the solvent was filtered through
a 0.22𝜇m pore size microfiltration membrane (Shanghai,
China). Next samples were processed via an Agilent 1260
HPLC system (Karlsruhe, Germany), including a quaternary
solvent delivery system, an on-line degasser, an autosampler,
a column temperature controller, and a photodiode array
detector coupled with an analytical workstation. Samples
were analyzed throughWaters SunFire C18 column (250mm
× 4.6mm, 5 𝜇m) at 30∘C. The binary gradient elution system
contained methanol and 0.2% phosphoric acid aqueous
solution, and separation was achieved using the following
gradient program: 0–15min, 97% B; 15-16min, 97–85% B;
16–45min, 85–50% B; 45–80min, 50% B. The flow rate
was set at 1.0mL/min and the sample injection volume was
10 𝜇L. The detection wavelength was at 273 nm for gallic acid
and 430 nm for curcumin. Data analysis was performed by
Similarity Evaluation System for Chromatographic Finger-
print of Traditional Chinese Medicine composed by Chinese
Pharmacopoeia Committee (Version 2009 A).
2.2. Animals and Drugs. Sprague-Dawley male rats (𝑛 =
40), weighing 180∼220 g, were purchased from the animal
center in Tongji Medical College of Huazhong University of
Science & Technology. All animals were housed at 22 ± 2∘C,
45–75% relative humidity, and 12 h light-dark cycles. They
were all able to freely access food and water and get 1-week
acclimation to the new environment before the experiment.
All the experimental procedures were performed following
the International Guidelines for Care and Use of Laboratory
Animals and approved by the Animal Ethical Committee of
the Institute of Health and Epidemic Prevention (Wuhan,
China). Tang-Kang-Fu-San (TKFS) was provided by Tibet
Autonomous Region Institute of Traditional TibetanHospital
(Lhasa, China). Metformin tablets were purchased from
Beijing Jing Feng Pharmaceutical Factory (Beijing, China).
2.3. Induction of Type 2 Diabetes Mellitus (T2DM). In a total
of 40 rats, 6 of them were randomly assigned to the normal
control group and fed with standard laboratory chow. The
other 34 rats were assigned to other experimental groups
to induce T2DM by a low-dose STZ and high-fat diet as
described [12]. Briefly, the rats were fed with high-fat diet
containing 20% carbohydrate, 20% protein, and 60% fat
(Research Diets Inc., New Jersey, USA) for 4 weeks followed
by an intraperitoneal (i.p.) injection of STZ (35mg/kg). 72
hours after STZ injection, the fast blood glucose in rats
was measured and only those rats with plasma glucose
levels ≥11.1mmol/L (referred to as hyperglycemia) were used
for next experiments. These 34 rats were fed with high-
fat diet throughout the whole study, and among them 1 rat
unfortunately died and 3 rats failed to develop hyperglycemia.
2.4. Experimental Design. T2DM rats were randomly divided
into five groups (𝑛 = 6 per group) as follows: T2DM
rats treated with vehicle (0.9% saline), T2DM rats treated
with 200mg/kg metformin, and T2DM rats treated with
0.3 g/kg, 0.6 g/kg, and 1.2 g/kg TKFS. The doses of TKFS
above were used for the rats because we converted the human
doses to rat-equivalent doses with scaling by body surface
area, according to instructions from that used in human
beings (6 g/day per adult). Both TKFS and metformin were
dissolved in 0.9% saline, and rats were treated by oral gavage
administration with doses described above once a day for
3 weeks. Among these 5 groups and normal control group
animals, their body weight and blood glucose were checked
weekly during the study.At day 18, their oral glucose tolerance
test (OGTT) was performed. At the end of day 21, all rats
were anesthetized with pentobarbital (40mg/kg body weight,
i.p.) and their blood was quickly collected from the hearts
and centrifuged at 4∘C and 3000 r/min for 15min and the
serum was collected and stored at −20∘C for biochemical
analysis.Thepancreas tissueswere dissected and immediately
immersed in 4% paraformaldehyde for histological analysis.
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The hindlimb skeletal muscle was dissected and immediately
frozen in liquid nitrogen for western blot analysis.
2.5. Fasting Blood Glucose (FBG) and Body Weight. FBG was
measured in a drop of blood from the tails by glucose oxidase
method using a glucometer (OneTouch, Ultra, LifeScan,
USA) once a week for three weeks (after plasma glucose
levels ≥11.1mmol/L). Their body weight was measured with
an electronic weighing scale.
2.6. Oral Glucose Tolerance Test (OGTT). For the OGTT, the
rats of all groups were fasted overnight and then orally loaded
with glucose (2 g/kg). 0, 30, 60, and 120min after glucose
administration blood samples were collected via the tail veins
and glucose levels were measured. The total area-under-the-
curve (AUC) of glucose of the sampling period from 0 to 120
minutes was determined by the following formula: the AUC
value = 1/4 × (BG0) + 1/2 × (BG30) + 3/4 × (BG60) + 1/2 ×
(BG120) [13].
2.7. Fasting Serum Insulin Levels (FINS) and Homeostasis
Model Assessment of Insulin Resistance (HOMA-IR) Analysis.
FINSweremeasured by using an enzyme-linked immunosor-
bent assay insulin ELISA kit (CSB-E05070r, CUSABIO
BIOTECH Co., Ltd, Wuhan, China). Homeostasis Model
Assessment-Insulin Resistance (HOMA-IR) was applied to
assess insulin resistance by the following formula: HOMA
score = fasting serum insulin (𝜇U/mL) × fasting glucose
(mmol/L)/22.5 [13, 14]. After logarithmic transformation the
statistical analysis was performed.
2.8. Biochemical Analysis. The total cholesterol (TC), triglyc-
erides (TG), LDL cholesterol (LDL-C), and HDL cholesterol
(HDL-C) levels in rat blood serum were determined with
absorption spectrophotometric analysis by an automatic
biochemical analyzer (Hitachi 7180 + ISE, Tokyo, Japan).
All results were analyzed and reported by the machine
automatically.
2.9. Histological Analysis of Pancreas Tissues. The pancreas
tissues were dissected and then fixed in 4%paraformaldehyde
overnight followed by dehydration and paraffin embedding.
The paraffin-embedded tissue specimens were sliced into
4 𝜇m thickness sections, which were mounted on glass slides
and stained with Hematoxylin and Eosin (HE) staining and
examined with a light microscopy (Olympus, Tokyo, Japan)
for histological analysis.
2.10. Western Blot Analysis. The total protein of the skeletal
muscle was extracted as described previously [15]. Next
the protein was fractionated on 10% SDS-PAGE and
transferred onto PVDF membrane. After blocking with
5% nonfat milk for 1 hour, the membranes were incubated at
4∘C overnight with primary antibodies: anti-AKT (#4685),
anti-phospho-AKTSer473 (#4060), anti-GLUT4 (#2213)
(CST, Massachusetts, USA), and anti-GAPDH (Proteintech,
Wuhan, China) diluted at 1 : 1000. Then the membranes
were washed in TBST and incubated with appropriate hors-
eradish peroxidase-conjugated secondary antibodies. The
protein bands were visualized by using a BeyoECL Plus
(P0018, Beyotime Biotechnology, China), and a densitometry
analysis was performed by BioRad Quantity One software
[13]. GAPDH was used as the internal control for semi-
quantitative analysis.
2.11. Statistical Analysis. All data were expressed as themeans
± SEM. GraphPad Prism 5 software was used for the data
statistical analysis and graphics. Unpaired t-test was used to
analyze statistical comparisons between two groups. Multiple
comparisons statistical significance were compared by one-
way ANOVA. 𝑃 value < 0.05 was assumed as statistically
significant.
3. Results
3.1.The Contents of Gallic Acid and Curcumin in TKFS. TKFS
mainly consists of Berberis kansuensis Schneid., Curcuma
longa L., Phyllanthus emblica, and so forth of 11 medicinal
herbs (from the product labels and data not shown). Our
developed method successfully determined their features,
especially those identities of gallic acid and curcumin in
TKFS (Figure 1). Contents of the two compounds in the sam-
ples are 0.16% and 0.24%. In the present study, since T2DM
rats were treated with 0.3 g/kg, 0.6 g/kg, and 1.2 g/kg TKFS,
the doses administered presented in the herbal formula with
gallic acid are 0.48mg/kg, 0.96mg/kg, and 1.92mg/kg and
with curcumin are 0.72mg/kg, 1.44mg/kg, and 2.88mg/kg,
respectively. The HPLC results showed that the linear ranges
of gallic acid and curcumin were 7.10–63.86 𝜇g/mL (𝑟 =
0.9998) and 5.24–47.40 𝜇g/mL (𝑟 = 0.9996), respectively.
The average recoveries were 98.41% with RSD of 2.04%
(𝑛 = 6) for gallic acid and 99.01% with RSD of 1.85%
(𝑛 = 6) for curcumin. It was concluded that the HPLC
method was simple and accurate with high sensitivity and
good repeatability which can be used for the determination
of phytochemical features of multiherbal formulae TKFS.
3.2. Effects of TKFS on Fasting Blood Glucose (FBG) and
Body Weight. The levels of FBG were higher in the rats of
the diabetic model control group than those of the normal
control group during all weeks we studied (all 𝑃 < 0.01).
After treatment with all different doses of TKFS, the levels of
FBG were significantly decreased compared with T2DM rats
treated with vehicle (𝑃 < 0.05 or 𝑃 < 0.01) (Figure 2(a)).
However, there was no significant difference in relative
body weight among all T2DM mice no matter treated with
different doses of TKFS, metformin, or vehicle (𝑃 > 0.05)
(Figure 2(b)).
3.3. Effects of TKFS on OGTT. Similar to FBG results, blood
glucose levels tested by OGTT in the T2DM rats treated with
vehicle were higher than those of the normal control group at
all time points after oral glucose administration (𝑃 < 0.01)
(Figure 3(a)). From the AUC of the five groups, we could
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Figure 1: The HPLC chromatogram of TKFS sample and reference substance at different detection wavelength ((a) gallic acid at 273 nm, (b)
TKFS sample at 273 nm, (c) curcumin at 430 nm, and (d) TKFS sample at 430 nm).
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Figure 2: Effects of TKFS on FBG (a) and body weight (b) in T2DM rats. ++𝑃 < 0.01 versus normal control group; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01
versus T2DMmodel group. Results are presented as means ± SEM (𝑛 = 6 each group).
observe an obvious reverse in blood glucose levels in the
TKFS- and metformin-treated groups compared with T2DM
rats treated with vehicle (𝑃 < 0.05 or 𝑃 < 0.01) (Figure 3(b)).
3.4. The Effect of TKFS on FINS and HOMA-IR Index. In
T2DM rats, dramatic increases in serum fasting blood insulin
and HOMA-IR index levels were observed. As shown in
Figures 4(a) and 4(b), both of them were decreased after
treatment of TKFS at 0.6 g/kg and 1.2 g/kg compared to
vehicle treatment. TKFS at 0.3 g/kg did not cause significant
changes in the FINS as compared with their vehicle controls
in T2DM rats (Figure 4(a)), but it did in the HOMA-IR index
significantly (Figure 4(b)).
3.5. Effects of TKFS on Plasma Lipid Parameters. Dyslipi-
demia was developed evidently in our T2DM rats as lipid
profile (TC, TG, and LDL-C) in serum was significantly
elevated in T2DM rats treated with vehicle compared to
normal control group (𝑃 < 0.01). TKFS- and metformin-
treated groups significantly reversed the rise in the levels
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Figure 3: Effects of TKFS on OGTT in T2DM rats. ++𝑃 < 0.01 versus normal control group; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus T2DMmodel
group. Results are presented as means ± SEM (𝑛 = 6 each group).
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Figure 4: Effects of TKFS on FINS (a) and HOMA-IR (b) index in T2DM rats. ++𝑃 < 0.01 versus normal control group; ∗𝑃 < 0.05 and ∗∗𝑃 <
0.01 versus T2DMmodel group. Results are presented as means ± SEM (𝑛 = 6 each group).
of serum TC, TG, and LDL-C in experimental T2DM rats
(Figures 5(a)–5(c)). Moreover, in T2DM rats, decreased level
of serum HDL-C was observed, and after treatment with
TKFS (0.3 g/kg, 0.6 g/kg, and 1.2 g/kg) for 21 days, it was
significantly increased (𝑃 < 0.01) (Figure 5(d)).
3.6. Effects of TKFS on the Pathomorphism of Pancreas
Tissues. Compared to the normal control rats (Figure 6(a)),
the T2DM rats (T2DM model control group, Figure 6(b))
showed more frequently pathological changes, such as atro-
phy of islet, islet cells necrosis, lacking organization of islet
cells, vanished pancreas and pancreatic acini boundaries, or
hypertrophy islet cells. Such histological changes were signif-
icantly alleviated in the TKFS (Figures 6(d), 6(e), and 6(f))
and metformin (Figure 6(c)) treatment groups compared to
the T2DMmodel control group.
3.7. The Effect of TKFS on p-AKT and GLUT4 Expres-
sion in Skeletal Muscle. To investigate whether intracellu-
lar PI3K/AKT pathway or GLUT4 on the cell membranes
might be responsible for the antidiabetic effects of TKFS,
protein levels in skeletalmuscle were assessed by determining
GLUT4 and the phosphorylated form of AKT (p-AKT).
As shown in Figure 7, the protein expression of p-AKT
and GLUT4 is significantly reduced in T2DM rats treated
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Figure 5: Effects of TKFS on TC, TG, LDL-C, and HDL-C in T2DM rats. TC (a), TG (b), LDL-C (c), and HDL-C (d); ++𝑃 < 0.01 versus
normal control group; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus T2DMmodel group. Results are presented as means ± SEM (𝑛 = 6 each group).
with vehicle compared with that in normal control group
(𝑃 < 0.01). Administration of TKFS at the three doses or
metformin for 3weekswas able to reverse the downregulation
of p-AKT (𝑃 < 0.05 at all three doses) andGLUT4 expression
in skeletal muscle (𝑃 < 0.01 at TKFS at 1.2 g/kg and 𝑃 < 0.05
at the other two doses).
4. Discussion
T2DM, the most common form of DM in diabetic patients
worldwide, is characterized by hyperglycemia, hyperlipi-
demia, and insulin resistance [1, 16]. A combined treatment
with the high-fat diet and low-dose STZ caused insulin-
resistant condition in rats and an elevation of plasma lipid
[17, 18], which developed a pathogenesis and process in
the T2DM rats perfectly resembling those in human T2DM
disease. Therefore we used the high-fat diet combined with
STZ-induced T2DM rats for this study.
Before animal work, from 13 chemical constituents in
TKFS we quantitatively characterized two of them, gallic acid
and curcumin (Figure 1), which turned out to be a remarkable
concurrence of their roles in antidiabetes as indicated before.
Gallic acid is a major component of extracts from natural
fruits or flower and so forth, for effective type 2 diabetes pre-
vention and treatment [19, 20]. In the last decades more than
7000 research publications had revealed the various perspec-
tives of curcumin, such as anti-inflammation, antioxidant,
and anticancer activities, as well as being famous for reversing
insulin resistance and hyperglycemia and alleviating diabetic
associated complications [21–23].
In our in vivo studies, we attempted to study antidiabetic
effects and the possible intracellular mechanisms of TKFS in
treating T2DM. To this end, we tested this agent in rats with
STZ-induced T2DM. In our study, high-fat diet fed-STZ-
induced diabetic rats developed a stably increased fasting
blood glucose and evident insulin resistance. After treatment
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Figure 6: Effects of TKFS on the pathomorphism of pancreas tissues in T2DM rats. Representative H&E staining images in pancreas paraffin
sections of different groups as marked above or below the pictures, respectively. Original magnification ×200.
with TKFS for 3 weeks, characteristic indices including
fasting blood glucose (Figure 2(a)), blood glucose follow-
ing OGTT and AUC of OGTT blood glucose (Figure 3),
and FINS and HOMA-IR index (Figure 4) were decreased
significantly in TKFS treated diabetic rats compared with
diabetic control rats. Therefore, TKFS can decrease both
blood glucose and insulin resistance in diabetes. Our results
also confirmed that the TKFS showed a strong hypolipidemic
effect as well as hypoglycemic effect through the reduction of
TG, TC, LDL-C, and elevation of HDL-C (Figure 5). Addi-
tionally similar to metformin, TKFS significantly rescued
the morphological abnormalities, which provided another
evidence that TKFS is capable of protecting pancreatic 𝛽-cells
(Figure 6).
The reports of metformin on reduction in body weight
gain are varied, depending on experimental animals, the
doses and length of time used, and so forth. Note that in the
present study, metformin treatment (200mg/kg for 3 weeks)
did not have obvious effects on reduction of the body weight
gain, consistent with one of our previous studies [12] and
other similar studies on mice [24, 25]. The “neutral” effect
of TFKS on body weight is rather surprising (Figure 2(b));
however, considering that a relatively large proportion of
T2DM patients are not obese at all particularly in Asian
countries [26], TKFS could be an adequate therapeutic for the
population of not obese T2DM patients.
To examine the possible mechanisms for TKFS playing
its therapeutic role, we measured p-AKT and GLUT4 lev-
els in skeletal muscle, since the activation of intracellular
PI3K/AKT pathway could excite translocation of GLUT4
enhancing glucose uptake and utilization [27, 28]. Down-
regulated p-AKT and the reduction in GLUT4 expression
were detected in skeletal muscle in T2DM model control
rats; however both of them were significantly restored with
TKFS treatment (Figure 7).These observations indicated that
promoting of p-AKT and GLUT4 activities is at least in
part responsible for TFKS exerting its effects on opposing
hyperglycemia and insulin resistance. Our data is very con-
sistent with a previous study performed in STZ-diabetic rats
treated with curcumin in yoghurt, which proved curcumin-
enriched yoghurt may promote a direct AKT activation and
further increase the GLUT4 translocation in skeletal muscle
[21]. Furthermore, such cohorts also strongly support those
nutraceutical compounds like curcumin or multiherbal for-
mulae like TKFS exert their effects through variousmolecular
targets and treat various diseases for anti-infectious, anti-
inflammatory, and even anticarcinogenic activities [21–23,
29], which may be of their potential advantages compared to
those well-known antidiabetics like metformin.
5. Conclusion
In the present study, we quantitatively analyzed the active
constituents of gallic acid and curcumin in TKFS. We also
found TKFS could effectively alleviate diabetic syndromes,
maintain the glucose homeostasis, and protect against insulin
resistance in high-fat diet and low-dose STZ-induced T2DM
rats. The underlying molecular mechanisms are at least
through activation of intracellular PI3K/AKT pathway and
promoting the translocation of GLUT4 in skeletal muscle.
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Figure 7: Effects of TKFS on p-AKTSer473 and GLUT4 in skeletal muscle in T2DM rats by western blot analysis. ++𝑃 < 0.01 versus normal
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